Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models.

Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ.

Mol Cancer Ther. 2019 Oct 9. pii: molcanther.0414.2019. doi: 10.1158/1535-7163.MCT-19-0414. [Epub ahead of print]


Prevalence of ADHD in Accident Victims: Results of the PRADA Study.

Kittel-Schneider S, Wolff S, Queiser K, Wessendorf L, Meier AM, Verdenhalven M, Brunkhorst-Kanaan N, Grimm O, McNeill R, Grabow S, Reimertz C, Nau C, Klos M, Reif A.

J Clin Med. 2019 Oct 8;8(10). pii: E1643. doi: 10.3390/jcm8101643.


Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.

Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaax0720. doi: 10.1126/scitranslmed.aax0720.


Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.

Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC.

Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5.


Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer.

Yasmin-Karim S, Bruck PT, Moreau M, Kunjachan S, Chen GZ, Kumar R, Grabow S, Dougan SK, Ngwa W.

Front Immunol. 2018 Sep 7;9:2030. doi: 10.3389/fimmu.2018.02030. eCollection 2018.


Subtle Changes in the Levels of BCL-2 Proteins Cause Severe Craniofacial Abnormalities.

Grabow S, Kueh AJ, Ke F, Vanyai HK, Sheikh BN, Dengler MA, Chiang W, Eccles S, Smyth IM, Jones LK, de Sauvage FJ, Scott M, Whitehead L, Voss AK, Strasser A.

Cell Rep. 2018 Sep 18;24(12):3285-3295.e4. doi: 10.1016/j.celrep.2018.08.048.


The rise of apoptosis: targeting apoptosis in hematologic malignancies.

Valentin R, Grabow S, Davids MS.

Blood. 2018 Sep 20;132(12):1248-1264. doi: 10.1182/blood-2018-02-791350. Epub 2018 Jul 16. Review.


Embryogenesis and Adult Life in the Absence of Intrinsic Apoptosis Effectors BAX, BAK, and BOK.

Ke FFS, Vanyai HK, Cowan AD, Delbridge ARD, Whitehead L, Grabow S, Czabotar PE, Voss AK, Strasser A.

Cell. 2018 May 17;173(5):1217-1230.e17. doi: 10.1016/j.cell.2018.04.036.


Loss of BIM augments resistance of ATM-deficient thymocytes to DNA damage-induced apoptosis but does not accelerate lymphoma development.

Delbridge AR, Grabow S, Strasser A.

Cell Death Differ. 2017 Nov;24(11):1987-1988. doi: 10.1038/cdd.2017.138. Epub 2017 Sep 8. No abstract available.


The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.

Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS, Herold MJ, Strasser A.

Cell Death Differ. 2017 Dec;24(12):2032-2043. doi: 10.1038/cdd.2017.125. Epub 2017 Aug 11.


The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL.

Delbridge AR, Aubrey BJ, Hyland C, Bernardini JP, Di Rago L, Garnier JM, Lessene G, Strasser A, Alexander WS, Grabow S.

Cell Death Dis. 2017 Jul 6;8(7):e2914. doi: 10.1038/cddis.2017.304.


Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival.

Viant C, Guia S, Hennessy RJ, Rautela J, Pham K, Bernat C, Goh W, Jiao Y, Delconte R, Roger M, Simon V, Souza-Fonseca-Guimaraes F, Grabow S, Belz GT, Kile BT, Strasser A, Gray D, Hodgkin PD, Beutler B, Vivier E, Ugolini S, Huntington ND.

J Exp Med. 2017 Feb;214(2):491-510. doi: 10.1084/jem.20160869. Epub 2017 Jan 5.


RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice.

Delbridge AR, Pang SH, Vandenberg CJ, Grabow S, Aubrey BJ, Tai L, Herold MJ, Strasser A.

J Exp Med. 2016 Sep 19;213(10):2039-48. doi: 10.1084/jem.20150477. Epub 2016 Sep 12.


Loss of PUMA (BBC3) does not prevent thrombocytopenia caused by the loss of BCL-XL (BCL2L1).

Delbridge AR, Chappaz S, Ritchie ME, Kile BT, Strasser A, Grabow S.

Br J Haematol. 2016 Sep;174(6):962-9. doi: 10.1111/bjh.14155. Epub 2016 May 25.


Physiological restraint of Bak by Bcl-xL is essential for cell survival.

Lee EF, Grabow S, Chappaz S, Dewson G, Hockings C, Kluck RM, Debrincat MA, Gray DH, Witkowski MT, Evangelista M, Pettikiriarachchi A, Bouillet P, Lane RM, Czabotar PE, Colman PM, Smith BJ, Kile BT, Fairlie WD.

Genes Dev. 2016 May 15;30(10):1240-50. doi: 10.1101/gad.279414.116. Epub 2016 May 19.


Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.

Grabow S, Kelly GL, Delbridge AR, Kelly PN, Bouillet P, Adams JM, Strasser A.

Cell Death Dis. 2016 Mar 10;7:e2132. doi: 10.1038/cddis.2016.43.


Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.

Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A.

Cell Rep. 2016 Mar 15;14(10):2337-47. doi: 10.1016/j.celrep.2016.02.039. Epub 2016 Mar 3.


Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies.

Delbridge AR, Grabow S, Strasser A, Vaux DL.

Nat Rev Cancer. 2016 Feb;16(2):99-109. doi: 10.1038/nrc.2015.17. Review.


Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.

Valente LJ, Grabow S, Vandenberg CJ, Strasser A, Janic A.

Oncogene. 2016 Jul 21;35(29):3866-71. doi: 10.1038/onc.2015.457. Epub 2015 Dec 7.


Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK.

Ke F, Grabow S, Kelly GL, Lin A, O'Reilly LA, Strasser A.

Cell Death Dis. 2015 Oct 22;6:e1938. doi: 10.1038/cddis.2015.304.


Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress.

Delbridge AR, Opferman JT, Grabow S, Strasser A.

Blood. 2015 May 21;125(21):3273-80. doi: 10.1182/blood-2015-01-621250. Epub 2015 Apr 6.


Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells.

Carrington EM, Zhang JG, Sutherland RM, Vikstrom IB, Brady JL, Soo P, Vremec D, Allison C, Lee EF, Fairlie WD, Bouillet P, Grabow S, Ottina E, Herold MJ, Pellegrini M, Huang DC, Tarlinton DM, Strasser A, Lew AM, Zhan Y.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4044-9. doi: 10.1073/pnas.1417620112. Epub 2015 Mar 16.


MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.

Sheikh BN, Lee SC, El-Saafin F, Vanyai HK, Hu Y, Pang SH, Grabow S, Strasser A, Nutt SL, Alexander WS, Smyth GK, Voss AK, Thomas T.

Blood. 2015 Mar 19;125(12):1910-21. doi: 10.1182/blood-2014-08-594655. Epub 2015 Jan 20.


MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.

Grabow S, Delbridge AR, Valente LJ, Strasser A.

Blood. 2014 Dec 18;124(26):3939-46. doi: 10.1182/blood-2014-09-601567. Epub 2014 Nov 3.


Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis.

Delbridge AR, Grabow S, Bouillet P, Adams JM, Strasser A.

Oncogene. 2015 Apr 2;34(14):1872-6. doi: 10.1038/onc.2014.132. Epub 2014 May 26.


Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.

Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD, Lee EF, Lindstrom MS, Wiman KG, Huang DC, Bouillet P, Rowe M, Rickinson AB, Herold MJ, Strasser A.

Genes Dev. 2014 Jan 1;28(1):58-70. doi: 10.1101/gad.232009.113.


Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice.

Kelly PN, Grabow S, Delbridge AR, Adams JM, Strasser A.

Cell Death Differ. 2013 Jan;20(1):57-63. doi: 10.1038/cdd.2012.92. Epub 2012 Jul 20.


Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.

Kelly PN, Grabow S, Delbridge AR, Strasser A, Adams JM.

Blood. 2011 Dec 8;118(24):6380-6. doi: 10.1182/blood-2011-07-367672. Epub 2011 Oct 12.


Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.

Grabow S, Waring P, Happo L, Cook M, Mason KD, Kelly PN, Strasser A.

Cell Death Differ. 2012 Apr;19(4):623-32. doi: 10.1038/cdd.2011.133. Epub 2011 Oct 14.


Membrane-bound Fas ligand only is essential for Fas-induced apoptosis.

O' Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A.

Nature. 2009 Oct 1;461(7264):659-63. doi: 10.1038/nature08402.


XIAP discriminates between type I and type II FAS-induced apoptosis.

Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A, Kaufmann T.

Nature. 2009 Aug 20;460(7258):1035-9. doi: 10.1038/nature08229. Epub 2009 Jul 22.

Supplemental Content

Loading ...
Support Center